Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells
暂无分享，去创建一个
K. Kiura | M. Tabata | K. Hotta | Y. Maeda | K. Ohashi | Hisao Higo | Naofumi Hara | Kazuya Nishii | E. Ichihara | K. Ninomiya | T. Kubo | Kammei Rai | Hirohisa Kano | H. Kayatani | Go Makimoto | H. Watanabe